We have previously shown that forced expression of CDK4 in mouse skin (K5CDK4 mice) results in increased susceptibility to squamous cell carcinoma (SCC) development in a chemical carcinogenesis protocol. This protocol induces skin papilloma development, causing a selection of cells bearing activating Ha-ras mutations. We have also shown that myc-induced epidermal proliferation and oral tumorigenesis (K5Myc mice) depends on CDK4 expression. Biochemical analysis of K5CDK4 and K5Myc epidermis as well as skin tumors showed that keratinocyte proliferation is mediated by CDK4 sequestration of p27
Introduction
Normal cell growth and differentiation requires precise control of the mechanisms that govern the entry into, passage through, and exit from the cell cycle. Progress through the G 1 phase of the mammalian cell cycle is mediated by D-type cyclins (D1, D2, and D3), which associate and activate CDK4 and CDK6 kinases, resulting in their catalytic activation and substrate recognition (1, 2) . CDK2 is considered a unique kinase that binds to cyclin E regulating S phase entry. The pRb family of proteins, pRb, p107, and p130, are key substrates for G 1 cyclin/CDK complexes, and negatively regulate the passage of cells from G 1 to S phase (2) . The Cip/Kip family of CDK inhibitors, p21
Cip1 , p27 Kip1 , and p57
Kip2
, form inactive complexes with CDK2-cyclin E and CDK2-cyclin A.
The Cip/Kip family members p21
Cip1 and p27 Kip1 also bind CDK4,6/ cyclin D complexes but do not interfere with their kinase activities (3, 4) . Thus, cyclin D-CDK4 may sequester p27 Kip1 , controlling the amount of p27
Kip1 available for inhibition of CDK2 activity. We and others have shown that indirect activation of CDK2 occurs by sequestration of p27
Kip1 upon forced expression of CDK4 (5-7). The role of CDK2 in cell proliferation has been supported by several founder reports in this field. A dominant-negative form of CDK2 prevents growth of cells in culture (8) , and microinjection of antibodies against CDK2, cyclin E, or cyclin A block initiation of DNA synthesis in mammalian cells (9) (10) (11) . However, in the last few years, the concept that CDK2 is crucial for control entry into S phase was challenged when two independent groups reported the generation of CDK2 À/À mice (12, 13) . These mice are viable, develop normally, and show defects in meiosis, but not in mitosis. Also, CDK2 seems to be dispensable for cell cycle inhibition and tumor suppression mediated by p27 Kip1 and p21 Cip1 (14) . Likewise, inhibition of CDK2 through expression of dominant-negative CDK2 or antisense oligonucleotides did not prevent cell proliferation of cancer cells in vitro (15) . On the other hand, genetic ablation of CDK4 has deep effect on normal cell proliferation and inhibition of tumorigenesis. CDK4
À/À mice are viable, but showed reduced size, suggesting growth retardation in several tissues. In fact, severe defects leading to degeneration of pancreatic islet and proliferative defects in the pituitary gland were observed (16) (17) (18) (19) . In addition, we and others have shown inhibition of tumor development in CDK4 À/À mice (20) (21) (22) .
Altogether, these data have led to the general concept that CDK4, but not CDK2, is an adequate target for therapeutic intervention. However, our previous studies showed that induction of keratinocyte proliferation by forced expression of CDK4 or myc is followed by CDK2 activation (7, 20, 23) . Moreover, we also showed that ablation of CDK4 results in the reduction of CDK2 activity in K5Myc/CDK4
À/À epidermis due to redistribution of p21 Cip1 and p27
Kip1 (23) . These results suggest that CDK2 activity is in part implicated in CDK4-mediated keratinocyte proliferation and skin tumorigenesis.
To investigate this hypothesis, we generated K5CDK4/CDK2
and K5Myc/CDK2 À/À compound mice. These models were used to study the role of CDK2 in ras-and myc-induced tumorigenesis. In this article, we show that CDK2 plays an important role in CDK4-induced keratinocyte proliferation. This study also shows that CDK2 contributes to the progression of mouse skin tumors carrying Ha-ras activating mutations. In addition, a decreased number of skin tumors and a strong reduction of malignant progression to squamous cell carcinomas (SCC) were clearly observed in K5CDK4/CDK2 À/À mice. However, we found that myc-induced tumorigenesis and keratinocyte proliferation was not responsive to CDK2 ablation. Overall, we have established that ras-induced tumors are more susceptible to CDK2 ablation than myc-induced tumors, suggesting that the efficacy of targeting CDK2 in tumor development and malignant progression is dependent on the oncogenic pathway involved.
Materials and Methods
Mouse experiments and pathologic analysis. K5CDK4, K5Myc, and CDK2-null mice were generated as previously described (7, 13, 24 Western blots and kinase assays. For immunoblotting, protein lysates were collected from epidermal skin scrapes with radioimmunoprecipitation assay lysis buffer, 150 mmol/L NaCl, 1.0% IGEPAL, 0.5% DOC, 0.1% SDS, 50 mmol/L Tris (pH 8.0). For immunoblot analysis of skin tumors, papillomas were snap frozen in liquid nitrogen and crushed with a pestle and mortar. Homogenates were sonicated and centrifuged at 14,000 rpm at 4jC. Supernatants were boiled in 2Â Laemlli sample buffer for Western blot analysis or stored at À80jC. To assess CDK2 and CDK1 kinase activities, proteins were extracted and immunoprecipitated in NP40 lysis buffer; Tris (pH 7.5), 150 mmol/L NaCl, 0.5% NP40, 50 mmol/L NaF, 1 mmol/L Na3VO4, P]ATP (6,000 Ci/mmol), 1 mmol/L DTT, and 5 Amol/L ATP were added to the bead pellet and incubated for 30 min at 30jC. SDS sample buffer was added, and each sample was boiled for 3 min to stop reaction and electrophoresed through polyacrylamide gels. Western blot and kinase assay bands were quantified using UN-SCAN-IT gel version 6.1 software for windows.
Immunostaining. For immunofluorescence, tissue cross-sections of formalin-fixed skin tumors were permeabilized using citrate antigen retrieval buffer, blocked with 10% normal serum, and stained with antibodies for keratin 5 (K5; Covance Research Products) and keratin 13 (K13; Novus Biological) followed by incubation with Alexafluor secondary antibodies (Molecular Probes). Epithelial cell proliferation was measured by i.p. injection of BrdUrd 30 min before the mice were sacrificed by CO 2 asphyxiation. BrdUrd incorporation was detected by immunohistochemical staining of paraffin-embedded skin sections with mouse anti-BrdUrd (Ab-2) monoclonal antibody (Calbiochem), biotin-conjugated anti-mouse antibody (Vector Laboratories, Inc.), and an avidin-biotin peroxidase kit (Vectastain Elite, Vector Laboratories) with diaminobenzidine as chromogen.
Statistical analysis. Statistical analysis was done using GraphPad Prism 4 Software (GraphPad Software).
Results

Biochemical and histologic evaluation of K5CDK4/CDK2
À/À mice. CDK2 expression has been largely implicated in induction of cell proliferation (8, 9, 11) ; however, ablation of CDK2 do not affect cell cycle progression in mice, but rather the meiotic process (12, 13) . We previously showed that overexpression of CDK4 in mouse skin results in increase epidermal proliferation associated with elevated CDK4 and CDK2 kinase activity, presumable due to sequestration of p27 Kip1 and p21 Cip1 (7, 20) . To investigate the role of CDK2 in CDK4-induced epidermal proliferation and malignant transformation, we have generated K5CDK4/CDK2 À/À compound mice. Consistent with our previous results, analysis of epidermal proliferation shows a 2-fold increase in the number of S-phase cells (BrdUrd-positive) in K5CDK4 epidermis compared with wild-type mice (Fig. 1) . On the other hand, CDK2-null mice do not show a difference in the level of keratinocyte proliferation compared with wild-type mice; however, ablation of CDK2 in K5CDK4 background 
(K5CDK4/CDK2
À/À mice) diminishes proliferation triggered by CDK4 overexpression (K5CDK4 mice; Fig. 1B ). Biochemical analysis of mouse epidermis shows that CDK2 ablation does not affect transgenic expression of CDK4 in K5CDK4/CDK2 À/À compound mice, which remain higher compared with wild-type littermate ( Fig. 2A) . Moreover, loss of CDK2 expression is not compensated for increased levels of endogenous CDK4 or CDK6, which although heterogeneous among siblings of same genotype, the levels of expression were similar between CDK2 À/À and wild-type mice ( Fig. 2A) . Consistent with previous description of our K5CDK4 model, we did not observe differences in Rb protein levels. In addition, we did not detect changes in protein mobility consistent with pRb phosphorylation ( Fig. 2A ; ref. 7) . In vitro kinase assay shows a 3.7-fold increase of CDK2 activity in epidermis from K5CDK4 mice ( Fig. 2B ; ref. 7). K5CDK4 mice shows increased CDK4 kinase activity (6.6-fold) compared with wild-type mice and, importantly, CDK2 ablation does not reduce this kinase activity (K5CDK4/CDK2 À/À mice, 7.2-fold increase; Fig. 2B ). Interestingly, the kinase activity of endogenous CDK4 is also augmented by 7.8-fold in CDK2 À/À epidermis compared with wild-type siblings ( Fig. 2B ). At present, we do not know the molecular mechanism underlying this increase of CDK4 activity, but whether this is a compensatory mechanism that is functional in keratinocytes and/ or other CDK2 À/À cells warrant further investigations. Recently, it has been shown that CDK1 can compensate the loss of CDK2 by binding to cyclin E and cyclin A; however, we did not observe increased CDK1 kinase activity in CDK2 À/À or K5CDK4/CDK2
À/À mice (25) (26) (27) . In fact, a mild reduction in CDK1 kinase activity was observed in keratinocyte lacking CDK2 expression (Fig. 2B) . We conclude that ablation of CDK2 does not affect normal keratinocyte proliferation, but reduces CDK4-induced hyperproliferation in mouse skin. CDK2 deficiency reduces skin tumor development and malignant progression. We previously showed that forced expression of CDK4 results in increase malignant progression to skin SCCs in a two-stage carcinogenesis protocol (20) . This protocol induces skin papilloma development by a single application of a carcinogen followed by biweekly treatment with a tumor promoter causing a selection of cells bearing Ha-ras mutations. To investigate the role of CDK2 in K5CDK4 skin tumorigenesis, we assessed the response of K5CDK4/CDK2 À/À to the two-stage carcinogenesis protocol. Four group of mice (K5CDK4, CDK2
, K5CDK4/CDK2 À/À , and wild-type; 20 newborns each) were treated with 50 Ag/200 AL of DMBA followed by two applications per week of 2.5 Ag of TPA after being weaned (21 days old). TPA treatment was continued for 25 weeks and the incidence and multiplicity of papillomas and SCCs were scored in each group for 40 weeks. Note that no spontaneous skin tumors were detected in untreated mice. The incidence of papilloma formation reaches a plateau at f15 weeks in K5CDK4 and wildtype mice, 100% and 97%, respectively (Fig. 3A) . A reduced tumor incidence was observed in CDK2 À/À and K5CDK4/CDK2 À/À , with each group reaching a plateau of 82% and 70%, respectively (Fig. 3A) . Ablation of CDK2 also results in decreased number of tumors per mouse (multiplicity). At 20 weeks of TPA promotion, the four groups of mice reached a plateau where reduced papilloma (20) . October 15, 2007 Research.
on April 14, 2017 . © 2007 American Association for Cancer cancerres.aacrjournals.org Downloaded from multiplicity was observed in K5CDK4 mice compared with wildtype littermates (8.5 and 6 papillomas per mouse, respectively; P < 0.05; Mann-Whitney U test; Fig. 3B ). CDK2 ablation results in the development of fewer papillomas in both CDK2
À/À and K5CDK4/ CDK2 À/À mice (3.5 tumors per mouse) compared with wild-type and K5CDK4 mice (P < 0.05; Mann-Whitney U test; Fig. 3B ). Consistent with our previous studies, SCCs develop rapidly and in greater number in K5CDK4 transgenic mice ( Fig. 3C; ref. 20) . The first SCC appeared at 22 weeks of promotion and 70% of K5CDK4 mice had developed SCC by 40 weeks of promotion. In sharp contrast, CDK2 ablation leads to a strong reduction of malignant progression because only 28% of K5CDK4/CDK2 À/À mice developed SCCs (P < 0.05; Fig. 3C ). K5CDK4/CDK2 À/À mice also exhibit an increased SCC latency period, where the first SCC was observed at 29 weeks of promotion. SCC incidence was similar between CDK2 À/À and wild-type groups where 15% to 20% of mice develop SCCs (Fig. 3C) . Histopathologic analysis was done with skin tumors of 30 to 40 weeks of promotion; papillomas and SCCs were graded according to a modified Broders classification system (28, 29) . This classification of SCCs breaks down this category into four type of tumors: (a) SCC I, well-differentiated SCC, most of the tumor mass composed of differentiated cells; (b) SCC II, moderately differentiated with f50% of differentiating cells; (c) SCC III, poor differentiated tumor with little keratinization, and (d ) SCC IV, poorly differentiated tumors with marginal or no keratinization, including spindle cell carcinomas (28, 30) . Most of the wild-type tumors analyzed were regular papillomas (60%) and 40% were classified as SCC I. On the other hand, analyzed skin tumors from K5CDK4 mice were classified as SCC I (45%), SCC II (25%), SCC III (5%), and papillomas (25%; Table 1 ). These data are consistent with our previous observation that forced expression of CDK4 increases the rate of malignant conversion (20) . In sharp contrast, only 43% of the K5CDK4/CDK2 À/À tumors analyzed were classified as SCC and all of them were well differentiated (SCC I) and no SCC grade II or III were observed in this group. Finally, CDK2 À/À mice showed a spectrum of tumors similar to wild-type littermates (Table 1) . Consistently, K5CDK4 carcinomas showed strong positive immunofluorescence staining for K13, a malignancy marker in squamous epithelia (31), whereas SCC from K5CDK4/CDK2 À/À mice were K13 negative (Fig. 4A) , further confirming that SCC from K5CDK4/CDK2 À/À mice were well-differentiated SCC and less aggressive than K5CDK4 SCC. Biochemical analysis of skin tumors from the four genotypes indicates that ablation of CDK2 results in a mild reduction in the transgenic expression of CDK4 in K5CDK4/CDK2 À/À compound mice (Fig. 4B , lines 5-7 and 8-10). The mechanism and consequences of this mild reduction in transgenic CDK4 expression warrants further investigation. Moreover, no compensation by CDK1 was observed in CDK2 À/À tumors, and all tumors showed similar level of pRb phosphorylation (Fig. 4B) . Interestingly, p15 Ink4b expression was reduced in K5CDK4 tumors independently of the CDK2 status (Fig. 4B) . We hypothesized that CDK4 expression increases Smad3 phosphorylation, resulting in inhibition of p15
Ink4b expression. Consistent with this hypothesis Liu et al. (32, 33) have shown that CDK4 and CDK2 phosphorylation of Smad3 inhibits its antiproliferative effects. Whether reduction of p15
Ink4 levels take part in the increase susceptibility of K5CDK4 mice to malignant transformation warrant further investigation. Finally, similar levels of CDK4 kinase activity were also observed in K5CDK4 and K5CDK4/CDK2 À/À tumors (data not shown).
We conclude that lack of CDK2 expression decreases papilloma development and more importantly abolishes malignant progression induced by forced overexpression of CDK4 in ras-dependent tumorigenesis.
Lack of CDK2 expression does not inhibit oral tumor development. Overexpression of the murine c-myc gene in the basal cell layer of epithelium (K5Myc mice) results in epidermal hyperplasia and hypertrophy (20, 24) . In addition, a high incidence of spontaneous tumors was observed in the oral mucosa of K5Myc transgenic mice (20, 24) . These results showed that myc acts as an oncogene in the stratified epithelium, but the mechanisms leading to the malignant phenotype are not fully understood. Interestingly, K5Myc mice exhibit elevated CDK4 protein levels and ablation of CDK4 inhibits myc tumorigenic activities in epithelial tissues and reduces CDK2 activity, presumably through redistribution of p27 Kip1 that bind and inhibit CDK2 (20) . To investigate whether CDK2 mediates the oncogenic activities of myc, we developed K5Myc transgenic mice that lack the expression of CDK2 (K5Myc/ CDK2 À/À mice). These mice, along with K5Myc, CDK2 À/À , and wild-type siblings, were analyzed for the development of spontaneous tumors. Histologic analysis of mice bearing the myc transgene revealed tumors of oral mucosa (Fig. 5A ). These tumors were classified as SCC consisting of islands, cords of neoplastic epithelial cells showing a variable degree of squamous differentiation with occasional keratin pearls in the centers. The invasive margins of the tumor are surrounded by proliferative fibrous connective tissue (Fig. 5A) . Oral tumors were observed in K5Myc mice as young as 8 weeks old with an incidence of f95%. In sharp (29, 30) . cNo atypia in basal layers. bWell-differentiated SCC; the tumor mass is mostly composed of differentiated cells.
x Moderately differentiated with f50% differentiating cells. k Poorly differentiated tumor with little keratinization; f10% to 25% of the tumor composed of differentiating cells. À/À SCC (c ). Note that the normal pattern of K5 expression (basal cell layer), as seen in wild-type papillomas, is lost in SCCs. SCCs from K5CDK4 mice (e) stain positive for K13 (red), a marker associated with malignant progression. Magnification, Â20; 4 ¶,6-diamidino-2-phenylindole (DAPI ; blue ) was used as nuclear counterstain. B, protein lysates from 30 wk papillomas obtained from wild-type (1 and 2), CDK2 À/À (3 and 4), K5CDK4 (5-7 ), and K5CDK4/CDK2 À/À (8-10 ) mice were separated by SDS-PAGE; transferred to nitrocellulose membrane; and blotted for CDK4, CDK2, CDK1, p15
Ink4b , and pRb. Actin was used as loading control. Hyperphosphorylation (ppRb ) and hypophosphorylation (pRb ) of retinoblastoma protein was denoted on the right. contrast to our previously published K5Myc/CDK4 À/À mice (20), K5Myc/CDK2 À/À mice develop tumors with similar frequency as K5Myc mice (93%; Fig. 5A ). Cell proliferation analysis of the oral cavity tumors did not reveal differences between the two genotypes (data not shown). Wild-type and CDK2 À/À littermates did not show any signs of spontaneous tumor development up to 18 months of age. Thus, mice with genetic ablation of CDK2 remain fully susceptible to myc-driven tumorigenesis of the oral mucosa. Collectively, these data indicate that CDK2 does not play a relevant role in the development of the spontaneous oral tumors observed in K5Myc mice. CDK2 is dispensable for c-myc-mediated keratinocyte proliferation. We also asked whether CDK2 mediates the epidermal hyperproliferative phenotype triggered by myc overexpression. Thus, we analyzed the epidermis of K5Myc and K5Myc/ CDK2 À/À mice. The skin of K5Myc mice exhibit epidermal hyperplasia (increase cell number) and increased keratinocyte proliferation (increase number of BrdUrd-positive cells; Fig. 5B and C). Abrogation of CDK2 expression (K5Myc/CDK2 À/À ) does not result in reversion on these variables, and the hyperkeratosis (accumulation of keratinized cells in the epidermal surface) characteristic of myc overexpression still persists (Fig. 5B) . Several reports have shown that myc induces the transcription of CDK4 (34) (35) (36) . Consistent with these results, we showed that CDK4 and myc overexpression results in CDK2 activation through sequestration of p27 Kip1 and p21 Cip1 by CDK4 (7, 20) . Furthermore, CDK2 activity was inhibited in K5Myc/CDK4
À/À epidermis, most likely due to redistribution of the CDK2 inhibitors p27
Kip1 and p21 Cip1 (20) . To evaluate whether expression and kinase activity of CDK4 was affected by the loss of CDK2 expression in K5Myc epidermis, we studied protein expression and in vitro kinase activity in epidermis from K5Myc/CDK2 À/À compound mice. Protein extracts from mouse epidermis were subjected to Western blot analysis for CDK4 and CDK2. Consistent with our previous results, the levels of CDK4 was 2-fold higher in K5Myc compared with wild-type epidermis, and the absence of CDK2 does not modify CDK4 expression (Fig. 2C) . As previously reported, the kinase activity of CDK4 increases 5.2-fold in K5Myc epidermis, compared with wild-type epidermis. Elevation in CDK4 kinase activity was also observed in K5Myc/CDK2
À/À epidermis (3.7-fold) compared with wild-type mice (Fig. 2D) . As expected, increased CDK2 kinase activity was observed in K5Myc mice (3-fold) due to sequestration of p27 Kip1 and p21 Cip1 by elevated levels of CDK4, whereas a baseline activity was observed in the other three genotypes ( Fig. 2D; ref. 20) . Collectively, these results indicate that CDK2 is dispensable for myc-induced epidermal proliferation.
Discussion
The concept that CDK2 is essential for controlled entry into S phase and the onset of DNA replication was challenged a few years ago when two independent groups reported the generation of CDK2 À/À mice (12, 13). These mice are viable, develop normally, and only show meiotic defects. These results were surprising, as CDK2 was thought to be required for promoting G 1 -S transition. In addition, it was also shown that cancer cells can proliferate in the absence of CDK2 (15) . Thus, the data accumulated in the last few years has brought the concept that CDK2 is not an adequate target for therapeutic intervention. In this article, we prove that CDK2 inhibition can still be considered as an adequate target for therapeutic intervention depending on the particular oncogenic pathway involved. We have previously shown that forced expression of CDK4 in mouse skin induces keratinocyte proliferation and malignant progression in a ras-dependent skin tumorigenesis model (7, 20) . À/À mice show similar levels of fibrosis and areas of invasion (arrows, top ). K, keratin pearls; De, dentin. Oral SCC formation, consisting of neoplastic epithelial cell cords with a variable degree of squamous differentiation and occasional keratin pearl in the centers. B, paraffin sections of skin from K5Myc/CDK2 À/À and control littermates stained with H&E. Wt, wild-type. Arrow, epidermis. C, quantification of the total number of nucleated cells per Â40 field. Original magnifications, Â20 (A) and Â40 (B).
Here, we have examined the skin of CDK2 À/À mice, which is structural and functional similar to that of wild-type siblings. It has been reported that CDK1 activation compensates for the absence of CDK2 in thymocytes, although this mechanism depends on the presence of p27 Kip1 (25) . However, biochemical analysis of CDK2 À/À epidermis shows reduction rather than activation of CDK1. We also observed increased activity of CDK4 in the epidermis of CDK2 À/À mice (Fig. 2B) . Because p27 Kip1 stabilize CDK4/D-type cyclin complexes (37) , it was possible that in the absence of CDK2, redistribution of p27
Kip1 increases CDK4/D-type cyclin/p27
Kip1 complex formation. Nevertheless, biochemical analysis did not show increased formation of those complexes (data not shown). Whether the increase in CDK4 activity compensates for the absence of CDK2 in the epidermis merits further investigation. The importance of the CDK4-CDK2 link in keratinocyte proliferation was shown by the activation of CDK2, through titration of p27/p21, by forced expression of CDK4 (refs. 7, 23; Fig. 2B ) and the reduction of the total number of proliferative cells in K5CDK4/ CDK2 À/À epidermis compared with K5CDK4 mice. Therefore, activation of both CDK4 and CDK2 kinases are necessary for epidermal hyperproliferation observed in K5CDK4 mice (Fig. 1) . We also studied whether CDK2 is required for CDK4-induced malignant progression to SCCs (20) . In our experimental setting, overexpression of CDK4 reduces papilloma multiplicity, although the number of mice with papilloma (incidence) was similar between K5CDK4 and wild-type mice. Lack of CDK2 leads to a significant reduction of papilloma incidence and multiplicity in K5CDK4/CDK2
À/À and CDK2 À/À mice. More importantly, lack of CDK2 expression in K5CDK4 mice (K5CDK4/CDK2 À/À mice) results in a severe reduction of CDK4-induced malignant progression to SCCs. Therefore, lack of CDK2 affects papilloma development and, more importantly, CDK2 expression is required for CDK4-induced malignant progression. Histopathologic analysis of tumors from the four genotypes confirms the role of CDK2 in malignant progression. Tumors from K5CDK4 mice were classified as regular papillomas and SCCs I, II, and III, whereas most of the K5CDK4/CDK2 À/À tumors were regular papillomas and no SCCs II or III were observed. In addition, K5CDK4 carcinomas showed areas of strong positive immunofluorescence staining for K13, a malignancy marker in squamous epithelia (31), whereas SCC from K5CDK4/CDK2 À/À mice were K13 negative.
We have previously shown that cyclin D1 and CDK4 expression plays an important role in papilloma development (38) (39) (40) (41) . We determined that cyclin D1 expression is not affected in CDK2 À/À papillomas (data not shown). The latter confirms that reduced papilloma formation and progression in CDK2 À/À and K5CDK4/ CDK2 À/À compound mice is not due to altered D-type cyclin levels.
We also observed a mild reduction of the expression of transgenic CDK4 in tumors from K5CDK4/CDK2 À/À mice compared with K5CDK4 siblings (Fig. 4B) . However, the CDK4 protein levels were still higher than wild-type mice. Thus, the reduction of transgenic CDK4 is not responsible for the reduction in the number of papillomas and SCC in K5CDK4/CDK2 À/À mice. Supporting these results, we previously reported that two independent K5CDK4 transgenic lines exhibiting different levels of CDK4 protein expression develop SCCs at a similar rate (20) . Similar to CDK1 expression in epidermis, CDK1 protein level was variable among tumors from the same genotype, but there are no relevant differences in CDK1 levels among the four genotypes. Interestingly, p15 Ink4b expression was reduced in K5CDK4 mice independently of the CDK2 status. p15
Ink4b transcription can be down-regulated via phosphorylation and inactivation of Smad3 by CDK4 (32, 33) , but decreased p15 Ink4b was observed in both K5CDK4 and K5CDK4/ CDK2 À/À , suggesting that its down-regulation is not responsible for the CDK4-induced malignant progression.
The present study allows us to define an important role of CDK2 in malignant progression. Interestingly, Duensing et al. (42) determined that CDK2 is dispensable for normal centrosome duplication, but required for oncogene-induced centrosome overduplication. Thus, lack of CDK2 could also abrogate the centrosome overduplication in epithelial tumor cells, protecting the cells against genetic instability, a mechanism involved in malignant progression. The present study also shows a reduction in the total number of chemically induced tumors in both CDK2 mice, which did not develop tumors (23) . Immunostaining analysis of myc-induced oral tumors revealed equal levels of proliferation (BrdUrd-positive cells) in the epithelial compartment of the oral tumors from K5Myc and K5Myc/CDK2 À/À mice (data not shown).
Thus, it is clear that lack of CDK2 does not affect the proliferation mediated by myc. To determine the effect of myc in other tissues, we also analyzed mouse epidermis from K5Myc and K5Myc/Cdk2 À/À mice. In contrast to the reduced proliferation mediated by lack of CDK4, ablation of CDK2 did not result in suppression of the epidermal phenotype observed in K5Myc mice. As we previously reported, overexpression of CDK4 was observed in K5Myc epidermis and it was not affected by CDK2 ablation (23, 36) . Consequently, lack of CDK2 cannot suppress the epidermal phenotype mediated by myc, suggesting that CDK4 plays a unique role in myc-induced keratinocyte proliferation (45, 46) . Thus, our results suggest that CDK2 is expendable for myc-induced proliferation not only in the gingival epithelium but also as a general characteristic for myc-induced proliferation in epithelial tissues. In addition to inducing proliferation, myc can also drive apoptosis, which serves as a barrier to unchecked cellular proliferation (47, 48) . In this sense, it was recently described that the removal of CDK2 suppressed the ability of myc to induce apoptosis (49). Thus, it is possible that loss of CDK2 reduces the myc-mediated apoptosis supporting tumor development. In summary, our data suggest that the efficacy of targeting CDK2 in tumor development and malignant progression is dependent on the specific oncogenic pathway involved. Similarly, other groups have shown that different oncogenic pathways respond differently to the inhibition of cell cycle regulators. For instance, cyclin D1-deficient mice are resistant to breast cancers induced by ras, but remains fully sensitive to other oncogenic pathways such as those driven by myc or Wnt-1 (50) . Also, CDK1 inhibition induces apoptosis in tumor cell lines transformed with myc, but not Ras or a variety of other activated oncogenes (51) .
Whether loss of CDK2 inhibits tumorigenesis mediated by other pathways such us neu or wnt remains to be determined. Overall, we have established that ras/CDK4-induced tumors are more sensitive to CDK2 inhibition than myc-induced tumors. Therefore, the suitability of CDK2 as a target for therapeutic intervention must be considered in the context of the particular pathway affected.
